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and intensity relative numbers. Results: In 2002, a total of 151,220 members were 
registered in 35 funds, increasing to 1,033,615 members in 31 funds by 2013. The 
total revenue of the health funds was HUF 6.699 billion in 2002, HUF 35.097 billion 
in 2007, and HUF 50.923 billion in 2013. The distribution of health fund payments 
as a percentage of consumption showed: in 2007, 88.4% supplementary health 
insurance services, including 16% supplementary services within the framework 
of social security benefits, 77% self-care services provided by the health funds (67.1% 
medicine, 31.2% medical device), while in 2013, 98.2% supplementary health insur-
ance services, including 18.6% supplementary services within the framework of 
social security benefits, 80.7% self-care services provided by the health funds (71.2% 
medicine, 28% medical device). Health fund payments for lifestyle improvement 
services reached 11.6% in 2007, and 1.5% in 2013. ConClusions: Reduction in the 
number of health funds, and an increase both in membership and revenues indicate 
the consolidation of the function of health funds. The distribution of payments 
by consumption shows no significant progress: medicine and medical device still 
play a major role, and disease prevention and health care services still represent 
a very small proportion.
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objeCtives: In the United States, Section 114 of the Food and Drug Modernization 
Act of 1997 (FDAMA) governs pharmaceutical companies’ promotion of health 
economic information to payers. Research shows that while payers frequently 
seek cost-effectiveness information, drug companies may hesitate to promote 
it because the law is unclear. The Food and Drug Administration (FDA) has not 
offered further guidance, although it suggested that it plans to publish draft guid-
ance in 2015. We developed hypothetical case studies of promotional claims and 
explored key questions about whether the FDA would allow them under Section 
114. Methods: We created ten categories of potential claims: 1) Costing out on-
label clinical endpoints, 2) Promotion of a costing exercise to physicians working in 
an accountable care organization settings, 3) Burden of illness claims, 4) Economic 
analyses of a formulary restriction policy, 5) Extrapolations to doses, populations, 
or settings not covered in trials, 6) Adherence claims, 7) “Utilization of care” as 
a secondary endpoint in randomized clinical trials, 8) Costing out a competitor 
drug’s adverse event, 9) Economic analysis of comparative effectiveness claims 
using an indirect treatment comparison, and 10) Extrapolating from surrogate to 
long-term outcomes in an economic model. We developed a case study for each. 
We sought to balance examples across diseases and to address the components 
of Section 114: information type, connection to labeled indication, audience, and 
evidence quality. Results: Most cases fall into a “gray area” as to whether they are 
allowable under Section 114. In particular, there is a lack of clarity about whether 
claims meet requirements that they be “directly related” to approved indications 
and supported by “competent and reliable scientific evidence.” ConClusions: 
This study reinforces the need for further guidance and/or legislation to clarify 
and possibly expand the Section. It also illustrates challenges the FDA faces in 
regulating this area.
PHP171
imPlementation of nice clinical Guidelines (cG) – WHat can Be 
learned from a uk case study and HoW to ensure tHat HealtH 
services do not fall sHort of tHeir oBliGations
Ranson P.1, Cline H.2, Hill C.A.1, Hill C.E.1, Marshall J.D.1, Harries M.1
1MAP BioPharma Limited, Cambridge, UK, 2Pinsent Masons LLP, London, UK
objeCtives: There is a perception that the National Institute of Health and Care 
Excellence (NICE) has struggled to get clinical commissioning groups (CCGs) to 
follow guidelines. There is a legal obligation to follow NICE technology appraisal 
guidance (TAG) when these are accompanied by a funding direction; however it 
has long been considered that this was not the case for Clinical Guidelines (CGs) 
nor is there any right of appeal in relation to CGs. We seek to demonstrate that 
CGs could be effectively mandatory unless a reasoned justification is provided. 
The position is contrasted with respect to guidance from technology apprais-
als. Methods: Case law and legislation are reviewed to compare the enforce-
ability of general guidelines and health technology appraisal-derived guidance. 
In particular Regina vs. North Derbyshire Health Authority, ex parte Fisher (1997) 
(Regina), and the recent decision of Rose vs. Thanet CCG (Rose) are referred to. 
We review both the CGs and TAGs issued and compare the strength and range of 
the recommendations. Results: The Reginacase established that a decision not 
to follow national policy was only lawful if there was some ‘special factor’, which 
‘exceptionally justified departure’. Disagreement with the policy was not enough. 
Following this, the recent Rose case considered that the CCG was under an implied 
obligation to give reasons for any general policy not to fund a particular inter-
vention, which suggests that the guidance is effectively mandatory unless there 
are special grounds. ConClusions: Even if the Rose decision were successfully 
appealed or distinguishable, CCGs will need to consider special circumstances if 
they do not wish to implement a CG. Along with financial constraints on health 
budgets, this creates dilemmas for CCGs including local priority setting. Therefore, 
as the law stands, exceptional circumstances will need to be identified by CCGs 
taking a contrary decision to a CG.
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sion, and 35% of them prefer to perform nutrition assessment during hospitaliza-
tion. ConClusions: Inappropriate nutrition care from healthcare providers was 
possibly due to the lack of appropriate guidelines and insufficient knowledge. 
Special nutrition management trainings and continuing professional develop-
ment (CPD) courses will be of great help to improve KAP of healthcare providers 
towards nutrition.
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objeCtives: The recent reforms and policy changes have increased the cost pres-
sures on all healthcare stakeholders, including clinical experts. In the past, clinical 
guidelines were developed independent of cost or economic considerations. However, 
increasingly, more clinical guidelines are mentioning cost concerns and referring to 
economic data in new recommendations. The objective of this study was to ana-
lyze trends in the use of health economic information for developing clinical guide-
lines. Methods: A systematic literature search was undertaken for the databases 
Pubmed, Embase, Biosis, Google Scholar, and Cochrane. The guidelines published 
between 2003-2012 were included. For guidelines which met the search criteria, data 
was collected for the name of the authors, indication, year of publication, country/
region, and context of use of cost/economic evidence. Results: Sixteen clinical 
guidelines published between 2003-2014 met the inclusion criteria for specific men-
tion of cost/economic evidence. More than 50% of these guidelines were published 
between 2006-2014. For indication, 3 out of 16 guidelines were for diabetes, while 
the rest were for different indications. In these16 guidelines “cost effectiveness” was 
mentioned 14 times, either referencing cost-effectiveness data or to mention the 
importance of such data for selecting treatment options. The guidelines commonly 
cite high cost of disease or high economic burden as one of the considerations for 
developing new recommendations (11 out of 16). Another term that was commonly 
used by these guidelines was “cost-benefit,” which was mentioned 5 times in these 
guidelines. Notably, QALY was rarely mentioned (1 out of 16 times) in these guide-
lines. ConClusions: This analysis suggests that some clinical experts groups are 
increasingly showing willingness to use and incorporate health economic information 
for developing new recommendations. Findings from this study might aid drug and 
device manufacturers in understanding the context of use of such information and 
allow them to tailor their product development plans for generating such evidence.
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objeCtives: To determine effectiveness of interventions for drug prescribing 
improvement in primary health care units. Methods: Systematic review and 
meta-analysis. Was held a quest in MedLine©, ScienceDirect©, Springer©, SciELO©, 
Dialnet©, RedALyC© and Imbiomed©, since indexation date of each database until 
August 2014. Were utilized keywords “drug prescribing”, “intervention studies” and 
“primary health care” with your synonyms. Were included quantitative studies, 
experimental and quasi-experimental, wrote in Spanish, English or Portuguese, 
and published in any country, with CASP-score equal or major than five, where 
drug-prescribing quality was evaluated accord to physicians’ adherence to drug 
posology and mexican guidelines for diseases treatment. Were excluded stud-
ies without raw data, qualitative studies, systematic reviews, protocols, essays, 
government documents, non-pharmacologic or alternative treatment studies 
and gray literature. Odds ratios (OR) with 95% interval confidence (p≤ 0,05) were 
obtained. Results: Were found 522 publications, were excluded 405 for title, 
99 for abstract and 9 for full text. Were included 3 references of the references. 
Don’t found references’ citations. Were analyzed 12 articles that reported 17 inter-
ventions: 64,7% educative, 23,5% incorporating of degreed in pharmacy to the 
health team, and 11,8% software utilization. The association forces “intervention/
improvement” obtained were: educative interventions OR= 2,47 (IC95% 2,28, 2,69), 
incorporating of degreed in pharmacy to the health team OR= 3,28 (IC95% 2,58, 
4,18), and software utilization OR= 10,16 (IC95% 8,81, 11,71). ConClusions: The 
software utilization interventions showed major effectiveness for to improve-
ment drug prescribing quality, versus educative interventions and incorporation 
of degreed in pharmacy to the health team. However, educative interventions may 
have a better cost-benefit relationship.
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objeCtives: Hungary runs a compulsory, solidarity based health insurance based 
system with a single payer. However, there is an increasing market of voluntary 
health insurance schemes and funds. The aim of this study is to analyze the vol-
untary health insurance market in Hungary. Methods: Our analysis is based on 
annual data from 2002 to 2013. The analysis of the number of funds and membership 
figures is based on end of the year data, the analysis of services and payments is 
based on annual data. We performed time series analysis and calculated dynamic 
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objeCtives: Outcomes-based pricing and reimbursement arrangements (OPRAs), 
a type of performance-based risk-sharing (PBRS) arrangements, have emerged as a 
promising avenue for payers to share pharmaceutical risk and for manufacturers to 
improve access. The aim of this study was to explore the U.S. and EU-5 perspectives 
regarding historical and future activity for OPRAs as well as payers’ and manufactur-
ers’ perceptions of OPRAs. Methods: Our study combined 2 approaches: targeted 
literature review and primary research with U.S. and EU-5 stakeholders. The targeted 
literature review included the following sources: University of Washington’s PBRS 
Database, payer and health technology assessment agencies’ websites, Factiva, 
PubMed, and congress abstracts. Only schemes relating to pharmaceuticals were 
included. Twenty-seven experts were interviewed using a structured questionnaire: 
14 US payers, 5 EU-5 national payers, 8 manufacturers’ pricing/market access execu-
tives (4 US, 4 EU-5). Results: A total of 117 arrangements were identified from 
1994 to 2014. This understates the level of OPRA activity as many schemes are 
confidential. U.S. and EU-5 interviewees expect that 2 to 10 times more OPRAs 
will be implemented in the next 5 years than in the previous 5 years. Historically, 
Italy has accounted for most OPRA activity; however, other nations are expected 
to increase OPRA activity. Key drivers include the introduction of a national OPRA 
framework in Spain, potentially a similar framework in the United Kingdom, a grow-
ing sick-fund activity in Germany, and a US movement towards accountable care. 
Motivation for OPRAs varies markedly across markets and stakeholders, with opera-
tional feasibility a significant hurdle in the U.S. and France. Cost and risk reduction 
were the primary focus for payers, while improving access was key for manufactur-
ers. ConClusions: This research suggests high OPRA growth is expected in the 
EU-5 and, to a lesser extent in the U.S., particularly if clear, uncomplicated OPRA 
frameworks can be developed.
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objeCtives: Pharmaceutical risk-sharing agreements are a type of contract 
between drug manufacturers and third party payers. These agreements are increas-
ingly being used as part of formulary listing decisions due to uncertainties about 
price and performance of new drugs at the time of launch. We develop a game 
theoretic model of a pay-for-performance agreement. Methods: We model inter-
actions between the payer and manufacturer as a Stackelberg game. The pharma-
ceutical firm chooses the drug price and then the payer chooses which patients 
will be eligible for treatment. Following treatment the manufacturer pays a rebate 
to the payer for all patients who did not respond to the new drug. We solve for the 
optimal price and treatment decisions by both parties. We define the social welfare 
as the sum of the payer’s and manufacturer’s objective functions, and investigate 
whether a combination of taxes, subsidies and additional rebates can result in the 
optimal social welfare when the two parties act independently in a decentralized 
system. Results: We examine how the rebate rate determines the payer’s optimal 
treatment decisions. Specifically, we find a break-even threshold for the rebate rate 
for which the payer incurs neither a loss nor gain for patients not responding to the 
drug. We create several numerical examples to investigate how the distribution of 
the probability of success throughout the population influences the manufacturer’s 
profits and the net health benefits purchased by the payer. We find that a single 
rebate based on performance does not, in general, lead to a socially optimal out-
come, but that that socially optimal outcome can be achieved through additional 
rebates or by using appropriately designed taxes and subsidies. ConClusions: A 
pay-for-performance risk-sharing agreement may be welfare-improving for certain 
ranges of rebate rate. Formulary managers should be aware of the incentives cre-
ated by different types of agreements when negotiating with drug manufacturers.
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objeCtives: In August/2014 the Brazilian government opened for public consulta-
tion its bill on public-private partnerships (PDPs). The aim of this study is to under-
stand the current situation of the public-private partnership in Brazil. Methods: 
We combined different database publicly available in the government website 
(www.saude.gov.br) encompassing: a) projects under analysis (submission period: 
March/2013-April/2014); b) products currently being purchased via PDPs; and c) 
projects rejected by the Ministry of Health. Results: There are 43 projects under 
analysis by the Ministry of Health, oncology representing over 50% of the submis-
sions. Government currently purchases 13 products from 7 official laboratories, vac-
cines being the main products. 151 projects were rejected by the Ministry of Health, 
participation of different therapeutic areas is fragmented. ConClusions: To this 
point, data shows that vaccines are the key products in the PDP arena. However, 
according to recent submissions, oncology seems also to be a field of interest.
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Two-Part Pricing for Patent Protected Medicines – An Economic Analysis from a 
Swedish Health Care Perspective Holm, H J and Hertzman, PobjeCtives: Many new 
medicines are targeting small patient populations. In order to recoup R&D costs the 
medicines are highly priced. A dilemma is that the price per patient (or pill or vial) can 
objeCtives: To asses and obtain data on the proper use of drugs and present irrational 
drug use pattern by medical practitioners that weather the patients receive the medi-
cines, weather these are appropriate for their clinical needs, in proper doses, for appro-
priate periods of time, weather cost effective and were dispensed properly. Methods: 
This study was designed to asses’ irrational drug use pattern which is a great concern of 
the entire world and WHO in general and in our country in particular. For this study we 
used the WHO indicators utilizing the services of trainee Pharmacists in two major city 
Hospitals. This study was conducted from April, 15th 2014 to May, 14th 2014. Data was 
collected using patient’s prescriptions and direct patient communication using a struc-
tured check list for the prescribing indicators including number of drugs per prescription, 
number of antibiotics, number of injections, number of steroids and number of food sup-
plements. The patient care data, including proper doses, proper timing, cost effectiveness 
and proper dispensing was directly interpreted and analyzed over the dispensing coun-
ters of Pharmacies by the trainee Pharmacists. Results: The results showed that in both 
hospitals (860 prescriptions), the average number of drugs per prescription were 5, the 
patients were prescribed antibiotics at least two antibiotics per prescription (40%).The 
percentage of injections, steroids and food supplements were 20% each. The percentage 
of proper doses, proper timing, cost effectiveness and proper dispensing was 70%, 60%, 
20% and 20% respectively. This irrational prescribing pattern/habit of the medical practi-
tioners was observed in both the hospitals. ConClusions: This study indicates that this 
type of irrational practice is the reflection of state and regulatory affairs in the country 
and this is a warning for all developing countries which need strict regulations and strat-
egies for drug prescriptions and dispensing including the utilization of services of more 
Pharmacists.
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objeCtives: Step therapy is defined as the practice of beginning drug therapy 
for a medical condition with the safest and most cost-effective drug therapy and 
progressing to more risky or costly therapies. This analysis assessed the number 
of US health plans that require patients to step through a branded boxed warning 
product before initiating a branded non-boxed warning product. Methods: This 
cross-sectional analysis was conducted using formulary data compiled by the MMIT 
Formulary Analytics Specialty Assessment database, which includes 2015 formulary 
status and policies for all US health plans. Of the 27 therapeutic classes that include 
products with a boxed warning, 9 therapeutic classes met all of the following criteria: 
(1) include currently marketed branded products, (2) include branded boxed warning 
products, (3) include branded non-boxed warning products, (4) include specialty or 
small-molecule products. Formulary requirements and restrictions for the 30 largest 
commercial US health plans were examined for cases in which patients are required 
by formulary design to step through a branded drug with a boxed warning before 
initiating a product without a boxed warning. Results: The 30 commercial plans 
represented 121 million lives, or 56% of the 217 million commercial lives in the United 
States. The number of health plans requiring patients to step through a branded 
boxed warning drug before initiating a non-boxed warning product in the 9 thera-
peutic classes included were: anti-infectives (miscellaneous), 0; anticonvulsants, 0; 
antidiabetics, 0; gastrointestinal agents, 0; immunological agents and biologics, 18 
(45% of covered lives); respiratory agents, 0; dermatologic agents, 0; central nervous 
system drugs (anti-Parkinson), 0; and renal agents, 0. ConClusions: The designs of 
US formularies generally do not require a step through products with a box warning 
prior to initiating a product without a boxed warning. The one notable exception is 
the class of immunological agents and biologics.
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objeCtives: To identify the key milestones for the public-private partner-
ships in Brazil. Methods: We conducted a literature review (2004-2014) on the 
legislation and local articles about public-private partnership (PPP) for drugs in 
Brazil. Results: In 2004 the government issued law #11079 establishing general 
rules for PPPs in all sectors. The first specific mention to healthcare was done in 
the article ‘Development, health-industrial complex and industrial policy’ (Gadelha, 
2006). In 2010 via the decree #1284 the government sets its list with the strategic 
products for the healthcare public system. Still in 2010 law #12349 creates the prefer-
ence margin benefiting in bids/tenders products locally produced. In 2013 in “Brasil 
Maior” plan the government formalizes its aim to achieving autonomy in producing 
strategic drugs via partnerships for productive development (PDP). More recently, 
public consultation #8 was opened in August/2014 with the content of the bill which 
aims to set criteria and guidelines for the PDPs. ConClusions: For the last 10 years 
the Brazilian government has consistently put in place either legislation or initiates 
to achieve autonomy in producing key products for the public healthcare system.
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